The Association of P2Y 12 Inhibitor Pretreatment With Length of Stay Among Patients With Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Graft Surgery: A Cohort Study
Cardiovascular Therapeutics · 2025
DOI: 10.1155/cdr/8959128 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Kramer J Wahlberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, The Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Coronary Artery Bypass, Length of Stay, Purinergic P2Y Receptor Antagonists, Acute Coronary Syndrome. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Recent clinical practice guidelines do not recommend routine P2Y 12 inhibitor pretreatment for patients with non‐ST‐elevation acute coronary syndromes (NSTE‐ACS) treated with an early invasive strategy based upon clinical trial data suggesting no improvement in clinical outcomes and increased risk of bleeding. A subset of patients with NSTE‐ACS who receive pretreatment and subsequently require coronary artery bypass graft (CABG) surgery may require lengthy P2Y 12 inhibitor washout to reduce periprocedural bleeding risk, potentially prolonging hospitalization and increasing costs. We sought to study the association of P2Y 12 inhibitor pretreatment on value‐based outcomes including length of stay, cost, and discharge destination.
Methods
We conducted a retrospective cohort study of patients presenting with NSTE‐ACS who underwent CABG at a tertiary academic medical center between 2019 and 2021. We assessed the frequency of P2Y 12 inhibitor pretreatment over the study period and compared risk‐adjusted length of stay, cost of hospitalization, and discharge destination among patients who did or did not receive pretreatment.
Results
One hundred eighty‐eight patients met inclusion criteria, and 77% received pretreatment. The rate of pretreatment decreased significantly over the study period ( p < 0.001). Pretreatment was associated with longer preoperative length of stay (4.2 ± 1.6 vs. 3.4 ± 2.5 days, p = 0.019), with no significant difference in postoperative or total length of stay. There was no difference in cost of hospitalization or likelihood of discharge to home following CABG.
Conclusion
Among patients presenting with NSTE‐ACS who underwent inpatient CABG, P2Y 12 inhibitor pretreatment was associated with longer preoperative length of stay, but no difference in total length of stay, cost of hospitalization, or discharge destination in this observational, single‐center study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, The Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
- Department of Medicine, The University of Vermont Medical Center, Burlington, Vermont, USA.
ORCID-Profile: Kramer J Wahlberg, Cyrus Thomas-Walker, Bradley J Tompkins, Juvena Hitt, Allen B Repp, William Hopkins
Zitieren
APA
Wahlberg, K. J., Thomas-Walker, C., Tompkins, B. J., Hitt, J., Repp, A. B., & Hopkins, W. (2025). The Association of P2Y 12 Inhibitor Pretreatment With Length of Stay Among Patients With Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Graft Surgery: A Cohort Study. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/8959128
Vancouver
Wahlberg KJ, Thomas-Walker C, Tompkins BJ, Hitt J, Repp AB, Hopkins W. The Association of P2Y 12 Inhibitor Pretreatment With Length of Stay Among Patients With Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Graft Surgery: A Cohort Study. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/8959128
BibTeX
@article{Wahlberg2025,
author = {Wahlberg, Kramer J and Thomas-Walker, Cyrus and Tompkins, Bradley J and Hitt, Juvena and Repp, Allen B and Hopkins, William},
title = {The Association of P2Y 12 Inhibitor Pretreatment With Length of Stay Among Patients With Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Graft Surgery: A Cohort Study},
journal = {Cardiovascular Therapeutics},
year = {2025},
doi = {10.1155/cdr/8959128}
}
EUVIMED